Cargando…

Recurrent idiopathic membranous nephropathy in the renal allograft: successful treatment with the anti-CD20 monoclonal antibody rituximab

Idiopathic membranous glomerulonephritis (IMGN) is one of the most common causes of nephrotic syndrome in adults. Disease progression is associated with the magnitude and duration of proteinuria [Reichert LJ, Koene RA, Wetzels JF. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ladino, Marco, Roth, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2009
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421397/ https://www.ncbi.nlm.nih.gov/pubmed/25949355 http://dx.doi.org/10.1093/ndtplus/sfp071

Ejemplares similares

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab
por: Merhi, Basma, et al.
Publicado: (2017)

Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
por: Wang, Yao-Wei, et al.
Publicado: (2023)

Early Recurrent Primary Membranous Nephropathy Detected in an Allograft Biopsy
por: Kaur, T., et al.
Publicado: (2019)

Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: Lu, Huijuan, et al.
Publicado: (2022)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review
por: Jeon, Soo-Jee, et al.
Publicado: (2022)

Retracted: Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
por: Blase, Jennifer R., et al.
Publicado: (2022)

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
por: Fotiou, Despina, et al.
Publicado: (2021)

Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience
por: Katsuno, Takayuki, et al.
Publicado: (2017)

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience
por: Chen, Ping, et al.
Publicado: (2023)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
por: Wada, Naoki, et al.
Publicado: (2009)

Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft
por: Von Visger, Jon, et al.
Publicado: (2019)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
por: Xue, Cheng, et al.
Publicado: (2023)

Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab
por: Belviso, Benny Danilo, et al.
Publicado: (2022)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
por: Eisenberg, R, et al.
Publicado: (2003)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy
por: Chen, Xinxin, et al.
Publicado: (2017)

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
por: Luo, Chengxin, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection
por: Hychko, G., et al.
Publicado: (2011)

Development and characterization of an anti-rituximab monoclonal antibody panel
por: Tada, Minoru, et al.
Publicado: (2018)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal
por: Rojas-Rivera, Jorge Enrique, et al.
Publicado: (2019)

Monoclonal immunoglobulin G deposits on tubular basement membrane in renal allograft: is this significant for chronic allograft injury?
por: Sawada, Anri, et al.
Publicado: (2019)

CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
por: Ramachandran, Raja, et al.
Publicado: (2016)

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma
por: Montraveta, Arnau, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9r57td6a2kbdr87067k0d2vi4c